Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Capital Expenditures (2017 - 2023)

Rhythm Pharmaceuticals (RYTM) has disclosed Capital Expenditures for 6 consecutive years, with -$1000.0 as the latest value for Q4 2023.

  • Quarterly Capital Expenditures changed 0.0% to -$1000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $47000.0 through Dec 2023, down 83.27% year-over-year, with the annual reading at $953000.0 for FY2025, N/A changed from the prior year.
  • Capital Expenditures for Q4 2023 was -$1000.0 at Rhythm Pharmaceuticals, down from $1000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $2.3 million in Q2 2019, with the low at -$1000.0 in Q4 2022.
  • Average Capital Expenditures over 4 years is $296214.3, with a median of $81500.0 recorded in 2021.
  • Peak annual rise in Capital Expenditures hit 958.33% in 2022, while the deepest fall reached 101.47% in 2022.
  • Over 4 years, Capital Expenditures stood at $259000.0 in 2019, then crashed by 73.75% to $68000.0 in 2021, then crashed by 101.47% to -$1000.0 in 2022, then changed by 0.0% to -$1000.0 in 2023.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at -$1000.0, $1000.0, and $47000.0 for Q4 2023, Q3 2023, and Q1 2023 respectively.